Shamburg News · 8-K filed Nov 13, 2026, 4:08 PM EST
Inhibrx Biosciences Reports Third Quarter 2026 Net Loss of $38.7 Million
INBX · Inhibrx Biosciences, Inc.
- Earnings
- Materiality: high
Inhibrx Biosciences, Inc. reported financial results for the three and nine months ended September 30, 2026. For the third quarter, the company recognized $2.0 million of license revenue from Pfizer, Inc. and reported a net loss of $38.7 million, or $2.46 per share, basic and diluted, compared with a net loss of $35.3 million, or $2.28 per share, in the prior-year quarter. Cash and cash equivalents were $199.5 million as of September 30, 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0002007919-26-000057.
Written from the filing by Shamburg Markets. Figures are as reported by the company.